NovaBridge Biosciences (NBP) Total Non-Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Total Non-Current Liabilities data on file, last reported at $29.1 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 152.34% year-over-year to $29.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.1 million (up 152.34% YoY) and the FY2025 annual result came in at $29.1 million, up 152.34% from the prior year.
• Total Non-Current Liabilities grew to $29.1 million in Q4 2025 per NBP's latest filing, from $11.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $145.8 million in Q2 2022 and bottomed at $11.5 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $30.9 million (2025), against an average of $57.8 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities surged 1572.79%; it then sank 88.07% in 2024.
• Tracing NBP's Total Non-Current Liabilities over 5 years: stood at $27.6 million in 2021, then climbed by 18.25% to $32.6 million in 2022, then surged by 48.89% to $48.6 million in 2023, then tumbled by 76.29% to $11.5 million in 2024, then soared by 152.34% to $29.1 million in 2025.
• Per Business Quant, the three latest NBP Total Non-Current Liabilities figures stand at $29.1 million (Q4 2025), $11.5 million (Q4 2024), and $14.9 million (Q3 2024).

Peer Comparison